-
Orforglipron vs. Semaglutide vs. Tirzepatide: The Ultimate 2026 Weight Loss Drug Comparison
May , 21 2026
1. Introduction: The GLP-1 Evolution The weight loss pharmaceutical market has dramatically shifted with the 2026 FDA approval of Orforglipron (Foundayo). This new oral, non-peptide agonist challenges...
read more
-
From Glucose Control to Liver Care: Semaglutide Becomes China's First GLP-1 Approved for MASH
Sep , 10 2026
A Boundary Crossed: GLP-1 Enters Hepatology On 10 September, China's National Medical Products Administration (NMPA) approved semaglutide injection (Wegovy®) for metabolic dysfunctio...
read more